THERAPEUTIC COMBINATIONS COMPRISING POLY(ADP-RIBOSE) POLYMERASES INHIBITOR

The invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by Formula (1) as a chemosensitizer that enhances the efficacy of cytotoxic drugs or radiotherapy. This invention provides pharmaceutical combinations of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DEWJI, MOHAMED, RAZA, JONES, CHRISTOPHER, CURTIN, NICOLA, JANE, KLAMERUS, KAREN, J, WILLIAMS, KAYE, JANINE, BORITZKI, THEODORE, JAMES, PLUMMER, ELIZABETH, RUTH, REICH, STEVEN, DAVID, THOMAS, HUW, DAVID, STRATFORD, IAN, J, KAUFMAN, RHONDA, NEWELL, DAVID, RICHARD, HOSTOMSKY, ZDENEK, STEINFELDT, HEIDI, MARIE, CALVERT, ALAN, HILARY
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention generally relates to use of 8-fluoro-2{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one represented by Formula (1) as a chemosensitizer that enhances the efficacy of cytotoxic drugs or radiotherapy. This invention provides pharmaceutical combinations of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, kits containing such combinations and methods of using such combinations to treat subjects suffering from diseases such as cancer. L'invention concerne l'utilisation de 8-fluoro-2{4-[(méthylamino)méthyl]phényl}-1,3,4,5-tétrahydro-6H-azépino[5,4,3-cd]indol-6-one de formule (1) en tant qu'agent chimiosensible qui améliore l'efficacité de médicaments cytotoxiques ou la radiothérapie. L'invention concerne des combinaisons pharmaceutiques de 8-fluoro-2{4-[(méthylamino)méthyl]phényl}-1,3,4,5-tétrahydro-6H-azépino[5,4,3-cd]indol-6-one, ou un de ses sels pharmaceutiquement acceptable et au moins un agent thérapeutique supplémentaire, des kits contenant les combinaisons et des procédés d'utilisation des combinaisons pour traiter les sujets souffrant de maladies telles que le cancer.